GSK

GSK raised its full-year 2025 forecast on Wednesday, citing strong sales of its specialty medicines and vaccines and recent drug approvals, including for its cancer treatment Blenrep.

GSK said Thursday its cancer drug Blenrep won U.S. approval to treat adults with multiple myeloma that has returned or stopped responding to treatment, overcoming an earlier negative recommendation from a regulatory advisory panel.

GSK announced positive late-stage trial results for a new, low-carbon version of its widely used Ventolin asthma inhaler.

GSK and partner Alector said Tuesday their experimental drug for a rare form of dementia failed to meet its main goal in a late-stage trial.

GSK and Spero Therapeutics on Tuesday announced positive late-stage trial results for their investigational oral antibiotic, tebipenem HBr, for treating complicated urinary tract infections (cUTIs).

GSK said on Tuesday that its shingles vaccine, Shingrix, has been approved in China for adults aged 18 and over who are at an increased risk of the disease.